港股異動 | 加科思-B(1167.HK)漲近5% SHP2抑制劑兩項聯合用藥臨牀試驗完成首例患者給藥
格隆匯6月18日丨加科思-B(1167.HK)漲近5%,報20.45港元,總市值158億港元。加科思公佈,公司加科思在研的SHP2抑制劑JAB-3312與帕博利珠單抗(Pembrolizumab)及貝美替尼(Binimetinib)的聯合用藥臨牀試驗,已分別在美國完成首例兩名患者給藥,這是一項針對治療晚期實體瘤患者的1/2a期臨牀試驗。根據雙方於2020年5月簽訂的許可及合作協議,這項臨牀進展將觸發公司與艾伯維(AbbVie)合作的里程碑付款條件,根據許可協議,公司將收到艾伯維2000萬美元的里程碑付款。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.